arrow_back Civic Audit
Share share

Increased Transparency for Biologic Drugs: Availability and Information.

New rules aim to increase transparency regarding the availability of biologic drugs on the market. Pharmaceutical companies will need to report more promptly whether their products are available for sale, making it easier for citizens and doctors to access up-to-date drug information.
Key points
Companies must report the marketing status of biologic products, including those discontinued or never available for sale.
Information on biologic drug availability will be regularly updated in public lists.
Increased transparency will help in better treatment planning and access to necessary products.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 117_S_4302
Sponsor: Sen. Kaine, Tim [D-VA]
Process start date: 2022-05-25
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Biologics Market Transparency Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_4302.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2022-05-25.

What are the main provisions?

Key points include:

  • Companies must report the marketing status of biologic products, including those discontinued or never available for sale.
  • Information on biologic drug availability will be regularly updated in public lists.
  • Increased transparency will help in better treatment planning and access to necessary products.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Kaine, Tim [D-VA].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

What is the impact of this bill?

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health